NCT00424554View on ClinicalTrials.gov

Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 26, 2006

Primary Completion Date

January 11, 2010

Study Completion Date

February 16, 2011

Conditions
Glioma
Interventions
DRUG

temozolomide

"Temozolomide 75 mg/m\^2 daily for 14 days prior to surgery.~As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00424554 - Low-dose Temozolomide for 2 Weeks on Brain Tumor Enzyme in Patients With Gliomas (P04602 AM1) (Completed) | Biotech Hunter | Biotech Hunter